Clinical and Translational Cancer Control Research Training Program

临床和转化癌症控制研究培训计划

• 批准号: 10163131
• 负责人: Michelle C Janelsins
• 金额: $ 31.85万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10163131
• 关键词: Cancer Control Research; Clinical; Training Programs

ABSTRACT This is a third competing renewal of the Clinical and Translational Cancer Control Research Training Program (CCRTP) R25T, transitioning into the T32 mechanism, led by Gary Morrow, PhD, MS, and Michelle Janelsins, PhD, MPH, of the University of Rochester (UR). The primary aim of the 2- to 3-year CCRTP is to provide MD and PhD trainees with the tools and experiences necessary to establish careers as outstanding independent investigators in cancer control research. This program fills an unmet need to train the next generation of cancer control investigators. As improvements in cancer treatments increase survival rates, there are 20 million cancer survivors and counting; these survivors continue to experience ongoing side effects that negatively impact quality of life. Thus, there is a greater need to better understand the numerous debilitating side effects of cancer treatment and develop interventions. The program combines didactic and “hands-on” research training activities. Dr. Janelsins, a former graduate of the CCRTP, formally joined Dr. Morrow as MPI in 2018 to enhance the translational science component of the CCRTP, providing synergy with Dr. Morrow’s expertise in clinical trials. For example, a number of recent trainees have focused on biologic mechanisms of intervention effects to alleviate side effects, or understanding biologic, medical, and psychologic risk factors for those who may develop side effects. Dr. Morrow and Dr. Janelsins are joined by 21 multidisciplinary, outstanding, experienced R01- funded mentors and 3 junior mentors with NCI K Awards from 12 academic departments, and exceptional infrastructure support from the NCI-funded Community Oncology Research Program (NCORP) Research Base, the UR Clinical and Translational Sciences Institute (CTSI), among others, as well as unparalleled institutional support from which to draw upon expertise to conduct and publish independent analyses and develop their own independent clinical and translational research projects. These research experiences are complemented by completion of a Master of Science (MS or MPH) degree focused in clinical investigation, epidemiology, translational research, health services, or data science. For our last 5 classes, 82 applicants (50 males/32 females, 18 MD/63 PhD, 8 minority) have been evaluated; 27 were invited for on-site interviews and 15 of the 16 who were offered positions accepted, including 5 minority applicants. They have produced 145 unique manuscripts, obtained several outstanding research awards, and earned $4.1 million in research funding. To date, 29 of the 31 trainees who have completed the program (last 15 years) have obtained tenure-track academic positions, and achieved a total of $63 million in independent funding, including 25 R-grants. Throughout our history, we have recruited approximately 50% women and 30% minority trainees. A majority (94%) of our trainees are still in academic cancer research-focused careers at Assistant (15), Associate (11), and Full (3) Professor level; some have also become leaders or directors of major programs within cancer centers. Our next renewal will continue to build upon this momentum of success.

抽象的 这是临床和转化癌症控制研究培训计划的第三次竞争更新 (CCRTP) R25T，过渡到 T32 机制，由 Gary Morrow 博士、硕士和 Michelle Janelsins 领导， 罗彻斯特大学 (UR) 博士、公共卫生硕士 2 至 3 年的 CCRTP 的主要目标是提供医学博士学位。 和博士生，拥有建立杰出独立职业所需的工具和经验 该计划填补了培训下一代癌症的未满足的需求。 随着癌症治疗的改进提高了生存率，有 2000 万癌症患者。 幸存者和计数；这些幸存者继续经历对质量产生负面影响的持续副作用 因此，我们更需要更好地了解癌症的众多使人衰弱的副作用。 该计划结合了教学和“实践”研究培训活动。 Janelsins 博士是 CCRTP 的前毕业生，于 2018 年正式加入 Morrow 博士担任 MPI，以加强 CCRTP 的转化科学部分，与 Morrow 博士在临床试验方面的专业知识发挥协同作用。 例如，最近的一些学员将重点放在干预效应的生物机制上 减轻副作用，或了解可能出现副作用的患者的生物、医学和心理风险因素 Morrow 博士和 Janelsins 博士由 21 名多学科、杰出、经验丰富的 R01- 加入。 来自12个学术部门的资助导师和3名获得NCI K奖的初级导师，以及杰出的导师 来自 NCI 资助的社区肿瘤学研究计划 (NCORP) 研究基地的基础设施支持， UR 临床和转化科学研究所 (CTSI) 等，以及无与伦比的机构 支持利用专业知识进行和发表独立分析并开发自己的 这些研究经验得到了独立临床和转化研究项目的补充。 完成理学硕士学位（MS 或 MPH），专注于临床研究、流行病学、 我们最后 5 门课程有 82 名申请者（50 名男性/32 名）。 女性（18 名医学博士/63 名博士，8 名少数民族）已接受评估；27 名受邀参加现场访谈，其中 15 名 16 名被录取的人，其中包括 5 名少数族裔申请人，他们已经产生了 145 名独特的人。 手稿，获得多项杰出研究奖，并获得 410 万美元的研究经费。 截至目前，完成该项目（过去 15 年）的 31 名学员中，有 29 名获得了终身教职学术学位 职位，并获得了总计 6300 万美元的独立资助，其中包括 25 项 R 补助金。 历史上，我们招募了大约 50% 的女性学员和 30% 的少数族裔学员，占我们学员的大多数 (94%)。 仍从事以癌症研究为重点的学术职业，担任助理 (15)、副 (11) 和正教授 (3) 教授 级别；有些人还成为癌症中心内主要项目的领导者或主任。 将继续巩固这一成功势头。